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Background: Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated with increased
morbidity and mortality. Studies regarding the status of MBD treatment in developing countries, especially in
Chinese dialysis patients are extremely limited.
Methods: A cross-sectional study of 1711 haemodialysis (HD) patients and 363 peritoneal dialysis (PD) patients
were enrolled. Parameters related to MBD, including serum phosphorus (P), calcium (Ca), intact parathyroid
hormone (iPTH) were analyzed. The achievement of MBD targets was compared with the results from the Dialysis
Outcomes and Practice Study (DOPPS) 3 and DOPPS 4. Factors associated with hyperphosphatemia were examined.
Results: Total 2074 dialysis patients from 28 hospitals were involved in this study. Only 38.5%, 39.6% and 26.6% of
them met the Kidney Disease Outcomes Quality Initiative (K/DOQI) defined targets for serum P, Ca and iPTH levels.
Serum P and Ca levels were statistically higher (P < 0.05) in the HD patients compared with those of PD patients,
which was (6.3 ± 2.1) mg/dL vs (5.7 ± 2.0) mg/dL and (9.3 ± 1.1) mg/dL vs (9.2 ± 1.1) mg/dL, respectively. Serum iPTH
level were statistically higher in the PD patients compared with those of HD patients (P = 0.03). The percentage of
patients reached the K/DOQI targets for P (37.6% vs 49.8% vs 54.5%, P < 0.01), Ca (38.6% vs 50.4% vs 56.0%, P < 0.01)
and iPTH (26.5% vs 31.4% vs 32.1%, P < 0.01) were lower among HD patients, compared with the data from DOPPS
3 and DOPPS 4. The percentage of patients with serum phosphorus level above 5.5 mg/dL was 57.4% in HD
patients and 47.4% in PD patients. Age, dialysis patterns and region of residency were independently associated
with hyperphosphatemia.
Conclusions: Status of MBD is sub-optimal among Chinese patients receiving dialysis. The issue of
hyperphosphatemia is prominent and needs further attention.
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Mineral and bone disorder (MBD) is a common compli-
cation of chronic kidney disease (CKD), and has been
associated with increased risk of cardiovascular calcifica-
tion, arterial dysfunction, morbidity and mortality [1,2].
Recently, increased attention has been focused on MBD,
and hyperphosphatemia is a central role. A meta-analysis
revealed that hyperphosphatemia is an independent risk
factor for mortality among CKD patients [3]. Gradual de-
cline in renal phosphorus clearance during the progres-
sion of CKD leads to an increase in serum phosphorus
concentrations [4], which plays an important role in
development of MBD [5]. Hyperphosphatemia may also
contribute to vascular calcification and therefore higher
risk of cardiovascular morbidity [1,2].
The Kidney Disease Outcomes Quality Initiative
(K/DOQI) clinical practice guidelines for MBD were
released in 2003, aiming at assisting nephrologists in
developing an integrated approach to the diagnosis and
management of MBD. Since then, studies have suggested
an improvement in treatment of MBD in many countries
[6,7]. However, studies regarding the status of MBD
treatment in developing countries are extremely limited,
where the accessibility to healthcare resources and struc-
ture of health care system are different. Therefore, the
Practice Patterns and Improvement Study of Bone
Metabolism and Disease in patients with CKD (PPIS) was
initiated to provide national data on the status of MBD
treatment among patients receiving dialysis in China.
Methods
Study population
Twenty eight renal divisions from 9 provinces in China
representing different geographic distribution and eco-
nomic status were recruited as a convenience sample on
a voluntary basis from January 2006 to June 2006. A
map marked with study centers is provided in Figure 1.
Adult ESRD patients receiving stable hemodialysis (HD)
or peritoneal dialysis (PD) for at least 3 months were
included in this study. Patients with renal tubule acid-
osis, multiple myeloma, idiopathic hypercalcemia or
metastatic carcinoma of bone were excluded from the
study. The ethics committee of Peking University First
Hospital approved the study. All participants gave writ-
ten informed consent prior to data collection.
Data collection
A questionnaire documenting information of sociode-
mographic status, personal and family health history,
dialysis prescription, and medication for MBD were fin-
ished by doctors or nurses. Then a blood sample were
drawn after an overnight fast of at least 8 hours, and be-
fore the HD session for HD patients. Parameters related
to MBD, including serum phosphorus, calcium andintact parathyroid hormone concentration (iPTH) were
measured at central laboratory of each study center.
Serum phosphorus and serum calcium were measured
by spectrophotometry assay. iPTH was measured by im-
munoradiometric or immunochemiluminometric assays.
Corrected calcium was calculated as total calcium
(mg/dL) + 0.8 × (4 - serum albumin (g/dL)).
Statistical analyses
Data were presented as proportions for categorical vari-
ables and mean ± standard deviation (SD) or median
[interquartile range (IQR)] for continuous variables.
Comparisons between HD and PD patients were made
using t - test or Wilcoxon rank-sum test for continuous
variables, and chi-square test for categorical variables.
According to the K/DOQI guideline [8], patients with
corrected serum calcium from 8.4 to 9.5 mg/dL (2.10 to
2.37 mmol/L), phosphate from 3.5 to 5.5 mg/dL (1.13 to
1.78 mmol/L) and iPTH from 150 to 300 pg/mL (150
to 300 ng/L) were considered optimal. The percentage
of participants within the optimal range and outside
the optimal range (above or below) was compared with
the results of Dialysis Outcomes and Practice Study
(DOPPS) 3 (2007) and DOPPS 4 (2010) [9].
Factors associated with hyperphosphatemia were ana-
lyzed using Logistic regression models. Factors in the
models included age (continuous), sex (female vs male),
dialysis pattern (PD vs HD), serum albumin level (con-
tinuous), hemoglobin level (continuous), and region of
residency (south vs. north).
All analyses were performed by SPSS statistical pack-
age, version 16.0 (SPSS, Inc., Chicago, IL). A P value of
less than 0.05 is considered statistically significant.
Results
Altogether 2074 patients were recruited, including 1711
HD patients and 363 PD patients. The average age was
57.5± 14.3 years, and 53.8% were males. The mean vin-
tage of HD and PD were 47.8± 41.2 months and
24.1± 20.0 months, respectively. Compared with HD
patients, PD patients were older, and had higher percent-
age of females. The main cause of ESRD was glomerulo-
nephritis (47.5%), while the percentage of diabetic
nephropathy was higher among PD patients compared
with HD patients (22.0% vs 8.9%) (Table 1).
Only 38.5%, 39.6% and 26.6% of participants were within
the optimal level of serum P, corrected serum Ca and
iPTH. There were no significant differences in percentages
of achievement of optimal target in plasma P, Ca and
iPTH between HD and PD patients. Serum P level and
percentage of patients with hyperphosphatemia were sta-
tistically higher in the HD patients compared with those
of PD patients, which was 6.3 ± 2.1 mg/dL vs 5.7 ± 2.0 mg/










Figure 1 A map marked with study centers.
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PD patients, but no significant differences in percentages
of patients with hypercalcemia or hypocalcemia. Serum
iPTH level were statistically higher in the PD patients
compared with those of HD patients (P= 0.03). And the
percentage of patients with low PTH was lower in PD
patients compared with HD patients (P < 0.001).
The percentages of patients with optimal P (37.6% vs
49.8% vs 54.5%, P < 0.01), Ca (38.6% vs 50.4% vs 56.0%,
P < 0.01) and iPTH (26.5% vs 31.4% vs 32.1%, P < 0.01)
were lower in HD patients, compared with those in the
DOPPS 3 and DOPPS 4 (Table 2).
Treatment regimen regarding MBD was different be-
tween HD and PD patients. More patients in HD were
prescribed with phosphorus binders than those of PDpatients (70.8% vs 64.0%,P = 0.03). More HD patients
were prescribed with vitamin D than PD patients (69.2%
vs 59.8%, P < 0.01). Compared with HD patients, the
mean dose of elemental calcium intake was lower in PD
patients (1.11 ± 0.67 g/day vs 0.91 ± 0.52 g/day, P < 0.01),
and fewer patients exceeded the 1.5 g/day limit sug-
gested by K/DOQI guidelines (30.4% vs 19.5%, P < 0.01).
All phosphorus binders used in those patients were
calcium-based binders. Among patients with serum
phosphorus level above 5.5 mg/dL, 27.4% of HD patients
and 25.0% of PD patients were not receiving any phos-
phorus binder. Actually in our study, 98% of patients
who were prescribed vitamin D used calcitriol.
Serum P level and percentage of patients with hyper-
phosphatemia were statistically higher in the South region
Table 1 Characteristics of the participants and comparison between HD and PD
Variables All participants (n = 2074) HD (n= 1711) PD (n= 363) P value
Age (years) 57.5 ± 14.3 57.1 ± 14.2 59.0 ± 14.4 0.03
Male (%) 53.8 55.8 44.1 < 0.001
Duration of dialysis (months) 33.6 ± 40.7 47.8 ± 41.2 24.1 ± 20.0 < 0.001
Cause of ESRD (%)
Glomerulonephritis 47.5 49.4 38.6 < 0.001
Hypertension 12.1 11.6 14.6 0.11
Diabetes 11.2 8.9 22.0 < 0.001
Interstitial nephritis 7.4 7.6 6.3 0.44
Obstructive nephropathy 2.4 2.4 2.5 0.85
Others 19.4 20.1 16.0 0.18
Hemoglobin (g/L) 101.0 ± 2.1 101.1 ± 2.0 99.3 ± 2.1 0.14
Serum albumin (mg/L) 37.5 ± 5.0 37.8 ± 4.8 36.1 ± 5.7 < 0.001
Corrected calcium (mg/dL) (%)
Mean ± SD 9.3 ± 1.1 9.3 ± 1.1 9.2 ± 1.1 0.03
< 8.4 19.4 19.4 19.4 1.00
8.4-9.5 39.6 38.6 44.0 0.07
> 9.5 41.0 42.0 36.6 0.06
Phosphorus binder prescription (%) 70.5 71.4 66.7 0.35
Vitamin D prescription (%) 61.2 64.6 43.2 < 0.001
Phosphorus (mg/dL) (%)
Mean ± SD 6.2 ± 2.1 6.3 ± 2.1 5.7 ± 2.0 < 0.001
< 3.5 5.8 5.0 9.6 < 0.01
3.5-5.5 38.5 37.6 43.0 0.06
> 5.5 55.6 57.4 47.4 < 0.01
Phosphorus binder prescription (%) 73.0 72.6 75.0 0.65
Vitamin D prescription (%) 66.6 66.5 67.5 0.85
iPTH (pg/mL) (%)
Median (IQR) 269.0 (132.0 - 472.9) 265.0 (127.2 – 456.3) 304.5 (162.0 – 486.7) 0.03
< 150 27.8 29.0 22.3 < 0.01
Vitamin D prescription (%) 48.1 52.3 23.5 < 0.001
150-300 26.6 26.5 27.3 0.74
Vitamin D prescription (%) 67.9 72.4 49.5 < 0.001
> 300 45.5 44.5 50.4 0.05
Vitamin D prescription (%) 78.2 77.5 81.2 0.34
Phosphorus binder prescription (%) 69.4 70.8 64.0 0.03
Vitamin D prescription (%) 67.4 69.2 59.8 < 0.01
Dialysate calcium (%)
1.25 mmol/L 19.0 19.9 15.1 0.08
1.5 mmol/L 58.2 68.7 12.8 < 0.001
1.75 mmol/L 22.8 11.4 72.1 < 0.001
Elemental calcium (g/day) 1.07 ± 0.65 1.11 ± 0.67 0.91 ± 0.52 < 0.001
> 1.5 g/day (%) 28.4 30.4 19.5 < 0.01
Abbreviations: HD, haemodialysis; PD, peritoneal dialysis; ESRD, end-stage renal disease; IQR, interquartile range; SD, standard deviation.
Kong et al. BMC Nephrology 2012, 13:116 Page 4 of 7
http://www.biomedcentral.com/1471-2369/13/116
Table 2 Comparison of HD and DOPPS 3 and DOPPS 4 in
mineral metabolism laboratory parameters
HD (n, %) DOPPS 3 (n, %) DOPPS 4 (n, %)
Corrected calcium(mg/dL)
<8.4 324 (19.4)* 791 (12.5) 904 (12.4)
8.4-9.5 647 (38.6)* 3195 (50.4) 4080 (56.0)
>9.5 703 (42.0)* 2355 (37.1) 2300 (31.6)
Phosphorus (mg/dL)
<3.5 86 (5.0)* 765 (11.0) 895 (11.3)
3.5-5.5 642 (37.6)* 3476 (49.8) 4337 (54.5)
>5.5 981 (57.4)* 2738 (39.2) 2722 (34.2)
iPTH (pg/mL)
<150 473 (29.0)* 2073 (36.8) 2325 (32.5)
150-300 431 (26.5)* 1767 (31.4) 2299 (32.1)
>300 724 (44.5)* 1787 (31.8) 2527 (35.3)
Abbreviations: HD, haemodialysis; DOPPS, Dialysis Outcomes and Practice
Study.
*P<0.01 (HD group vs. DOPPS 3 and DOPPS 4).
DOPP 3(2007) and DOPP4 (2010): Includes data from AusNZ, Belgium, Canada,
Germany, Italy, Japan, Spain, Sweden, UK, and US only.
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which was 6.7 ± 2.2 mg/dL vs 5.7 ± 1.8 mg/dL (P< 0.001)
and 65.8% vs 45.6% (P< 0.01), respectively. To the best of
our knowledge, the availability of phosphorus binders or
vitamin D is not different in north and south China. And
in our study, 70.5% patients in South region and 68.4%
patients in North region were receiving phosphorus
binder (P=0.41). But more patients in North region were
prescribed with vitamin D than those patients in South
region (72.3% vs 62.7%, P = 0.045).
Table 3 presents the logistic regression analysis of
hyperphosphatemia and various parameters. After
adjusting for sex, serum albumin and hemoglobin, age,
dialysis patterns and region of residency were still inde-
pendently associated with hyperphosphatemia.Table 3 The logistic regression analysis for






Age 0.99 (0.98-0.99) 0.99 (0.98-0.99)
Sex (female vs. male) 0.82 (0.69-0.99) 0.88 (0.73-1.07)
Dialysis patterns (PD vs. HD) 0.72 (0.57-0.92) 0.74 (0.57-0.95)
Serum albumin 1.00 (0.98-1.01) 1.00 (0.98-1.02)
Hemoglobin 1.00 (0.99-1.00) 1.00 (1.00-1.01)
region of residency
(South vs. North)
2.14 (1.78-2.57) 2.15 (1.77-2.62)
OR* was adjusted for age, sex, dialytic patterns, serum albumin, hemoglobin,
region of residency.
Abbreviations: OR, odds ration; CI, confidence interval.Discussion
In our cross-sectional survey involving various geo-
graphic regions in China, the treatment of MBD was
found to be sub-optimal among patients receiving
mountainous dialysis. Uncontrolled hyperphosphatemia
is especially prominent.
Hyperphosphatemia is an independent risk factor for
both mortality [1,10,11] and renal function decline in
CKD patients [12,13]. A recent analysis of DOPPS [7]
indicated that the lowest mortality was seen among
patients with serum phosphorus 3.6 to 5.0 mg/dL, and
higher mortality was observed in facilities with a higher
proportion of patients with serum phosphorus greater
than 6.0 mg/dL. Similarly, a meta-analysis indicated that
the risk of death increased by 18% for every 1.0 mg/dL in-
crease in serum phosphorus (relative risk of 1.18, 95% CI
1.12-1.25) in individuals with CKD [3]. Compared with
results from DOPPS, control of hyperphosphatemia in
our study is sub-optimal, which may be related to the fol-
lowing factors. Firstly, restriction of dietary phosphorus is
the primary strategy for controlling hyperphosphatemia.
Unfortunately, nutritionist was not available for most HD
and PD centers in China. In our analysis, although we did
not have information of dietary intake of phosphorus,
residency in southern China was observed to be an inde-
pendent risk factor for hyperphosphatemia. It is well
known that in southern China, foods containing rich
phosphorus (eg. seafood and meat soup) are more likely
to be consumed than in Northern China. A study using
24-hour dietary recalls also indicated that phosphorus in-
take was higher among Southern Chinese compared with
that of Northern Chinese, which was 562± 67 mg/
1000 kcal and 378± 76 mg/1000 kcal, respectively [14].
Secondly, insufficient use of phosphorus binder was
observed in our analysis. On the other hand, 46.5% of
patients with serum calcium level above 9.5 mg/dL still
were using calcium-containing phosphorus binder. In
China, non-containing calcium phosphorus binders were
not available. Therefore, inappropriate application of
phosphorus binder may be related to hyperphosphatemia.
Finally, our analysis revealed that HD was independently
associated with higher risk of hyperphosphatemia, com-
pared with PD patients. It has been shown that certain
hemodialysis prescription may increase phosphorus clear-
ance. Nocturnal HD [15,16] and short daily HD [17,18]
was shown to reduce serum phosphorus levels and re-
quirement for phosphorus binders. Membrane surface
area itself has a potentially important impact on phos-
phorus removal. In a recent study in 18 patients over a
period of 6 weeks, doubling of membrane area by the use
of 2 dialyzers in parallel (with blood flow equally split be-
tween the dialyzers) resulted in a 1.34 mg/dL decline in
predialysis serum phosphorus levels compared with con-
ventional HD [19]. A recent randomized controlled trial
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tion on hyperphosphatemia among 493 patients [20]. It
was shown that phosphorus levels decreased from
5.18± 0.10 mg/dL at baseline to 4.87± 0.10 mg/dL at
6 months in hemodiafiltration patients (P < 0.001) and
were stable in low-flux HD patients (5.10 ± 0.10 mg/dL at
baseline and 5.03± 0.10 mg/dL after 6 months, P = 0.5).
After adjustment for phosphorus binder use, hemodiafil-
tration still have an advantage of improving phosphorus
control over low-flux HD. In our study, low-flux HD was
applied in the majority of our dialysis centers, which may
also be related to poor phosphorus control. In summary,
reducing phosphorus intake under the instruction of nu-
tritionist, proper use of phosphorus binder, and adopting
dialysis prescription with better phosphorus clearance
may improve the sub-optimal treatment of hyperpho-
sphatemia in China.
In K/DOQI guidelines, the optimal PTH levels was
recommended to be 150-300 pg/ml for dialysis patients,
which was based on the predictive ability of PTH for
low-and high-turnover bone disease [8]. However, the
early studies of MBD parameters evaluated survival as a
function of a single time point baseline measurement of
PTH, thereby ignoring important changes in the param-
eter [11]. Conversely, time dependent approaches are
influenced strongly by events immediately proximal to
the outcome and therefore may reflect worsening para-
meters caused by rapidly declining health status [10,21].
More recently, there have been attempts at using
cumulative-effects models by the Hemodialysis (HEMO)
Study investigators to better capture the relationship be-
tween bone mineral metabolism parameters and sur-
vival, and they also have found higher ceilings for PTH
levels than previous work [22]. Analysis from the
DOPPS also revealed an increased risk for all-cause mor-
tality (not cardiovascular mortality) only when
PTH> 600 pg/mL [7]. Therefore, in the recently released
guidelines from the kidney Disease: Improving Global
Outcomes (KDIGO), it is suggested that iPTH levels
should be maintained in the range of approximately two
to nine times the upper limit of normal for patients re-
ceiving dialysis [23]. In our study, about 56.7% of partici-
pants met the KDIGO target for PTH. However, more
studies (especially interventional studies) are needed to
verify the range suitable for better clinical outcome. In
our study, the proportion of PD patients with PTH less
than 150 pg/mL is not higher than HD patients. This
may be related to the relatively low proportion of dia-
betes in PD patients and with short time on dialysis.
To date, there is no DOPPS-equivalent study looked
at the management of mineral metabolism in PD
patients. Compared with the data from Canadian PD
patients [24], the present study demonstrated that the
percentage of patients reached the K/DOQI targets forCa (44.0% vs 44.7%) and iPTH (27.3% vs 28.4%) were
similar among PD patients. However, the percentage of
patients with hyperphosphatemia (> 5.5 mg/dL) and
hypercalcemia (> 9.5 mg/dL) were higher than Canadian
PD patients, which were 47.4% vs 21.2% and 36.6% vs
16.7%, respectively. It indicates that based on K/DOQI
guidelines, Chinese PD patients are not within optimal
target ranges and there is room for improvement.
Our study has several limitations that deserve men-
tion. Firstly, study sites were enrolled on a voluntary
basis, which might introduce bias. However, most of par-
ticipants came from tertiary hospitals. Therefore, the dir-
ection of bias would be to overestimate the control rate
of MBD. Secondly, some information of factors related
to the MBD were not available in our study, such as diet,
residual renal function, dialysis prescription and dialysis
adequacy. Thirdly, laboratory tests were not performed
in one central laboratory, therefore variability of meas-
urement may affect the interpretation of our results. The
same limitation exists for the comparison between our
study and DOPPS study. Fourthly, the demographic
characteristics and medical conditions of patients in our
study might be different from those of participants in
DOPPS study, which might contribute to the difference
in parameters of MBD. Finally, the cross-sectional de-
sign limited our ability to make causal inference.Conclusion
Our national survey indicated that the status of MBD
treatment is sub-optimal among Chinese patients receiv-
ing dialysis. The issue of hyperphosphatemia is promin-
ent and needs to be improved. Multiple measures
including dietary phosphorus restriction, oral phos-
phorus binders including non-containing calcium phos-
phorus binders and dialysis model should be optimized
to improving the control of hyperphosphatemia, which
in turn may reduce the risk for vascular calcification and
cardiovascular mortality.
Competing interests
The authors declare that they have no competing interests.Author’s contributions
K XL and Z LX participated in the study, analyzed the data, interpreted the
results, and drafted the manuscript. Z L, C N, G Y, Y XQ, L WH, C JH, P LR, Y
WJ, W H, C W, F MH, H LQ, D F, C XM, X ZY, Z JY, J Q, S W, X CY, T XL, H FF,
S GY, M CL, W L, X DM and N ZH participated in the survey and study
design and collected the data. Z L participated in the survey and study
design and interpreted the results. W M formed the study concept,
interpreted the results, and revised the manuscript. Wang HY revised the
manuscript for important intellectual content. All authors read and approved
the final manuscript.Acknowledgments
We would like to acknowledge The Roche Pharma. for generous
sponsorship.
Kong et al. BMC Nephrology 2012, 13:116 Page 7 of 7
http://www.biomedcentral.com/1471-2369/13/116Author details
1Renal Division, Department of Medicine, Peking University First Hospital;
Peking University Institute of Nephrology; Key Laboratory of Renal Disease,
Ministry of Health of China; Key Laboratory of Chronic Kidney Disease
Prevention and Treatment (Peking University), Ministry of Education, Beijing,
China. 2Department of Nephrology, China-Japan Friendship Hospital, Beijing,
China. 3Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong
University, School of Medicine, Shanghai, China. 4Renal Division, Xinhua
Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
5Department of Nephrology, the First Affiliated Hospital, Sun Yat-sen
University, Guangzhou, China. 6Department of Nephrology, Beijing Friendship
Hospital, Capital Medical University, Beijing, China. 7Kidney Diseases Center,
First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,
China. 8Department of Nephrology, Beijing Chaoyang Hospital, Capital
Medical University, Beijing, China. 9Department of Nephrology, Shanghai First
People s Hospital, Shanghai Jiaotong University, Shanghai, China.
10Department of Nephrology, Beijing Hospital, Beijing, China. 11Department
of Nephrology, Xijing Hospital, Fourth Military Medical University, Xi’an,
China. 12Department of Nephrology, Peking University Third Hospital, Beijing,
China. 13Department of Nephrology, Shuguang Hospital, Shanghai University
of Traditional Chinese Medicine, Shanghai, China. 14Department of
Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
15Department of Nephrology, The General Hospital of the People's Liberation
Army, Beijing, China. 16Renal Division, Hospital Peking of Shenzhen,
Shenzhen, China. 17Department of Nephrology, The 455th Hospital of PLA,
Shanghai, China. 18Department of Nephrology, Xuanwu Hospital, Capital
Medical University, Beijing, China. 19Department of Nephrology, Guangdong
General Hospital, Guangzhou, China. 20Renal Division, Jiangsu Provincial
Hospital, Nanjing, China. 21Department of internal medicine, Shantou Central
Hospital, Shantou, China. 22Department of Nephrology, Nanfang Hospital,
The Southern Medical University, Guangzhou, China. 23Department of
Nephrology, Fujian Provincial Hospital, Fuzhou, China. 24Department of
Nephrology, Changzheng Hospital, Second Military Medical University,
Shanghai, China. 25Department of Nephrology, Sichuan Provincial People’ s
Hospital, Chengdu, China. 26Department of Nephrology, Qianfoshan Hospital,
Shandong University, Jinan, China. 27Renal Division, Renji Hospital, Shanghai
Jiao Tong University School of Medicine, Shanghai, China. 28Department of
Nephrology, Peking University People’s Hospital, Beijing, China. 29Institute of
Nephrology and Division of Nephrology, and Key Laboratory of Ministry of
Health, Peking University First Hospital, 8 Xishiku Street, Xicheng District,
Beijing 100034, China.
Received: 13 December 2011 Accepted: 14 September 2012
Published: 21 September 2012References
1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM:
Mineral metabolism, mortality, and morbidity in maintenance
hemodialysis. J Am Soc Nephrol 2004, 15(8):2208–2218.
2. Hruska KA, Saab G, Mathew S, Lund R: Renal osteodystrophy, phosphate
homeostasis, and vascular calcification. Semin Dial 2007, 20(4):309–315.
3. Palmer SC, Hayen A, Macaskill P, et al: Serum levels of phosphorus,
parathyroid hormone, and calcium and risks of death and cardiovascular
disease in individuals with chronic kidney disease: a systematic review
and meta-analysis. JAMA 2011, 305(11):1119–1127.
4. Levin A, Bakris GL, Molitch M, et al: Prevalence of abnormal serum vitamin
D, PTH, calcium, and phosphorus in patients with chronic kidney
disease: results of the study to evaluate early kidney disease. Kidney Int
2007, 71(1):31–38.
5. Gutierrez O, Isakova T, Rhee E, et al: Fibroblast growth factor-23 mitigates
hyperphosphatemia but accentuates calcitriol deficiency in chronic
kidney disease. J Am Soc Nephrol 2005, 16(7):2205–2215.
6. Wald R, Tentori F, Tighiouart H, Zager PG, Miskulin DC: Impact of the
Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice
Guidelines for Bone Metabolism and Disease in a large dialysis network.
Am J Kidney Dis 2007, 49(2):257–266.
7. Tentori F: Mineral and bone disorder and outcomes in hemodialysis
patients: results from the DOPPS. Semin Dial 2010, 23(1):10–14.
8. K/DOQI clinical practice guidelines for bone metabolism and disease in
chronic kidney disease: Am J Kidney Dis 2003, 42(4 Suppl 3):S1–S201.9. Dialysis Outcomes and Practice Patterns Study: DOPPS annual report. 2010.
http//www.dopps.org/annual report/index.htm.
10. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al: Survival predictability of
time-varying indicators of bone disease in maintenance hemodialysis
patients. Kidney Int 2006, 70(4):771–780.
11. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum
phosphorus and calcium x phosphate product with mortality risk in
chronic hemodialysis patients: a national study. Am J Kidney Dis 1998,
31(4):607–617.
12. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP: Association of
disorders in mineral metabolism with progression of chronic kidney
disease. Clin J Am Soc Nephrol 2006, 1(4):825–831.
13. Kovesdy CP, Kalantar-Zadeh K: Serum phosphorus and the risk of
progression of chronic kidney disease. Nephrol Dial Transplant 2007,
22(12):3679–3680.
14. Zhao L, Stamler J, Yan LL, et al: Blood pressure differences between
northern and southern Chinese: role of dietary factors: the International
Study on Macronutrients and Blood Pressure. Hypertension 2004,
43(6):1332–1337.
15. Walsh M, Manns BJ, Klarenbach S, Tonelli M, Hemmelgarn B, Culleton B: The
effects of nocturnal compared with conventional hemodialysis on
mineral metabolism: A randomized-controlled trial. Hemodial Int 2010,
14(2):174–181.
16. Pierratos A, Ouwendyk M, Francoeur R, et al: Nocturnal hemodialysis:
three-year experience. J Am Soc Nephrol 1998, 9(5):859–868.
17. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S: Effects of short
daily versus conventional hemodialysis on left ventricular hypertrophy
and inflammatory markers: a prospective, controlled study. J Am Soc
Nephrol 2005, 16(9):2778–2788.
18. Maduell F, Navarro V, Torregrosa E, et al: Change from three times a week
on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney
Int 2003, 64(1):305–313.
19. Tonelli M, Wang W, Hemmelgarn B, Lloyd A, Manns B: Phosphate removal
with several thrice-weekly dialysis methods in overweight hemodialysis
patients. Am J Kidney Dis 2009, 54(6):1108–1115.
20. Penne EL, van der Weerd NC, van den Dorpel MA, et al: Short-term effects
of online hemodiafiltration on phosphate control: a result from the
randomized controlled Convective Transport Study (CONTRAST). Am J
Kidney Dis 2010, 55(1):77–87.
21. Melamed ML, Eustace JA, Plantinga L, et al: Changes in serum calcium,
phosphate, and PTH and the risk of death in incident dialysis patients: a
longitudinal study. Kidney Int 2006, 70(2):351–357.
22. Wald R, Sarnak MJ, Tighiouart H, et al: Disordered mineral metabolism in
hemodialysis patients: an analysis of cumulative effects in the
Hemodialysis (HEMO) Study. Am J Kidney Dis 2008, 52(3):531–540.
23. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention,
and treatment of Chronic Kidney Disease-Mineral and Bone Disorder
(CKD-MBD): Kidney Int Suppl 2009, 76(113):S1–S130.
24. Soroka SD, Beard KM, Mendelssohn DC, Cournoyer SH, Da Roza GA, Geary
DF: Mineral metabolism management in Canadian peritoneal dialysis
patients. Clin Nephrol 2011, 75(5):410–415.
doi:10.1186/1471-2369-13-116
Cite this article as: Kong et al.: Mineral and bone disorder in Chinese
dialysis patients: a multicenter study. BMC Nephrology 2012 13:116.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
